Reply to Bauer and Goff

Clinical Infectious Diseases

Volumn 61, Issue 3, 2015, Pages 487-488

  Mylonakis, Eleftherios ^a   Clancy, Cornelius J ^b   Ostrosky Zeichner, Luis ^c   Garey, Kevin W ^d   Alangaden, George J ^e   Vazquez, Jose A ^f   Groeger, Jeffrey S ^g   Judson, Marc A ^h   Vinagre, Yuka Marie ⁱ   Heard, Stephen O ^j   Zervou, Fainareti N ^a   Zacharioudakis, Ioannis M ^a   Kontoyiannis, Dimitrios P ^k   Pappas, Peter G ^l  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

^e Henry Ford Health System Division of Infectious Diseases   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WINTHROP UNIVERSITY HOSPITAL   (United States)

ⁱ St Vincent Hospitals   (Australia)

^j UMASS MEMORIAL MEDICAL CENTER   (United States)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^l University of Alabama at Birmingham   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANDIDA; CANDIDEMIA; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC PROCEDURE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; LETTER; PRIORITY JOURNAL; T2CANDIDA PANEL; FEMALE; ISOLATION AND PURIFICATION; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PROCEDURES;

CANDIDA; CANDIDEMIA; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE;

EID: 84938576467     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ357     Document Type: Letter

References (10)

1. Bauer KA, Goff DA. When diagnostic technology is ahead of the hospital budget: what is antimicrobial stewardship to do? Clin Infect Dis 2015; 61:486-7.
2. Mylonakis E, Clancy CJ, Ostrosky-Zeichner L, et al. T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. Clin Infect Dis 2015; 60:892-9.
3. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014; 27:490-526.
4. Bodenheimer T. High and rising health care costs. Part 2: technologic innovation. Ann Intern Med 2005; 142:932-7.
5. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27:781-8.
6. Aitken SL, Beyda ND, Shah DN, et al. Clinical practice patterns in hospitalized patients at risk for invasive candidiasis: role of antifungal stewardship programs in an era of rapid diagnostics. Ann Pharmacother 2014; 48: 683-90.
7. Bilir SP, Ferrufino CP, Pfaller MA, Munakata J. The economic impact of rapid Candida species identification by T2Candida among high-risk patients. Future Microbiol 2015; doi:10.2217/fmb.15.29.
8. Farmakiotis D, Tarrand JJ, Kontoyiannis DP. Drug-resistant Candida glabrata infection in cancer patients. Emerg Infect Dis 2014; 20:1833-40.
9. Guillamet CV, Vazquez R, Micek ST, Ursu O, Kollef M. Development and validation of a clinical prediction rule for candidemia in hospitalized patients with severe sepsis and septic shock. J Crit Care 2015; doi:10.1016/j.jcrc.2015.03.010.
10. Cleveland AA, Harrison LH, Farley MM, et al. Declining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillance. PLoS One 2015; 10:e0120452.